金沙国际电玩城

Mingqian FENG

来源: 责任编辑:陈华夏 发布:2020-05-28 点击量:


undefined

 

Professor

Fengmingqian@mail.hzau.edu.cn

Tel: 02787282669

 

 

Research Interest:  

Our lab is focusing on translational medicine studies, with the ultimate goal of developing cancer immunotherapy drugs and technologies. Currently, we are focusing on antibody-derived therapeutics and adoptive transfer of engineered of immune cells. For the antibody-derived therapeutics, we are working at bi-specific antibody and antibody-drug conjugate (ADC). In particular, we’re interested in understanding the role of cancer specific membrane proteins in tumor biology and generating novel antibody-based therapeutic agent targeting tumor biomarkers. One of the examples that we’re working with is liver cancer biomarker GPC3 and the hippo-yap pathway. For the engineering of immune cells, we are working at the new generation of chimeric antigen receptor-modified immune cells.

We also have broad interest in antibody engineering filed, including but not limited to, antibody display technologies (phage display, yeast display, mammalian display), domain antibodies (camelid, shark, human, and other protein scaffold-derived binders), antibody-drug conjugation, and modification of antibody characteristics (enhanced ADCC and CDC, prolonged half-life, improved stability, etc.).

 

Education: 

1993.09-1997.07 B.A. Northwestern Agricultural University, majored in Crop Genetics and Breeding, Yangling, Shaanxi 712100, China

1997.09-2000.07 M.S. Northwest Agriculture & Forestry University, majored in Biochemistry and Molecular Biology, Yangling, Shaanxi 712100, China

2005.09-2008.06, Ph.D. Nanjing University, majored in Biology, Nanjing, Jiangsu 210093, China

Professional Experiences:

2000.07-2005.09, Instructor on Biochemistry and Molecular Biology, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, Hubei 430070, China

2008.10-2013.10, Post-doctoral training in antibody engineering, Laboratory of Molecular Biology (LMB), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD.

2013.10-2015.11, Research Fellow, National Cancer Institute, NIH, Bethesda, MD

Selected Publications:

1. Xin Chen, Norhan Amar, Yuankui Zhu, Chunguang Wang, Chunjiao Xia, Xiaoqing Yang, Dongde Wu, Mingqian Feng*. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth. Journal for Immunotherapy of Cancer. 2020DOI: 10.1136/jitc-2020-000785 (in production)

2. Dan Li, Nan Li , Yi-Fan Zhang, Haiying Fu, Mingqian Feng, Dina Schneider, Ling Su, Xiaolin Wu, Jing Zhou, Sean Mackay, Josh Kramer, Zhijian Duan, Hongjia Yang, Aarti Kolluri, Alissa M Hummer, Madeline B Torres, Hu Zhu, Matthew D Hall, Xiaoling Luo, Jinqiu Chen, Qun Wang, Daniel Abate-Daga, Boro Dropublic, Stephen M Hewitt, Rimas J Orentas, Tim F Greten, Mitchell Ho. Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice. Gastroenterology 2020; 158(8):2250-2265.

3. Zhe Duan, Jingqiu Liu, Liping Niu, Jun Wang, Mingqian Feng*, Hua Chen*, Cheng Luo*. Discovery of DC_H31 as potential mutant IDH1 inhibitor through NADPH-based high throughput screening. Bioorganic Medicinal Chemistry 2019; 27(15):3229-3236.

4. Mingqian Feng#, Hejiao Bian#, Xiaolin Wu, Tianyun Fu, Jessica Hong, Bryan Fleming, Martin Flajnik, Mitchell Ho. Construction and next-generation sequencing analysis of a large phage-displayed VNAR single domain antibody library from six naïve nurse sharks. Antibody therapeutics, 2019, 2:1-11

5. Wei Gao, Heungnam Kim, Mingqian Feng, Yen Phung, Charles P Xavier, Jeffrey S Rubin, Mitchell Ho. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signaling and protein synthesis. Nature Communications 2015; 6:6536.

6. Mingqian Feng, Wei Gao, Ruoqi Wang, Weizao Chen, Yan-Gao Man, William Douglas Figg, Xin Wei Wang, Dimiter S Dimitrov, Mitchell Ho. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. PNAS 2013; 110(12):E1083-91.

7. Mingqian Feng, Jingli Zhang, Miriam Anver, Raffit Hassan, Mitchell Ho. In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice. Journal of Cancer 2011; 2:123-31.

8. Liping Yu#, Mingqian Feng#, Heungnam Kim, Yen Phung, David E Kleiner, Gregory J Gores, Min Qian, Xin Wei Wang, Mitchell Ho. Mesothelin as a potential therapeutic target in human cholangiocarcinoma. Journal of Cancer 2010; 1:141-9.

Patents

1. CN201911146557.5. 丰明乾,陈鑫,左殿宝,何慧侠,杨柳. TIM-3单域抗体及其应用. 2019.11.20

2. PCT/US2012/034186. Mitchell Ho, Mingqian Feng, Wei Gao, Hungnam Kim, and Dimiter S. Dimitrov. Human monoclonal antibodies specific for glypican-3 and use thereof. 10/26/2012.

3. PCT/US2013/059883. Mitchell Ho, Ira Pastan, Dimiter S. Dimitrov, Zhewei Tang, Mingqian Feng, and Wei Gao. Mesothelin antibodies and methods for eliciting potent antitumor activity. 04/03/2014


CopyRight©2001-2015 College of Life Science and Technology, Huazhong Agricultural University

E-mail:bio@mail.hzau.edu.cn